Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
1Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
2Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
3Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy
4Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy
5Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
6Department of Occupational Medicine, University Hospital of Bari, Bari, Italy
7Section of Environmental and Occupational Epidemiology and Ergonomics, University Hospital of Bari, Bari, Italy
8Department of Occupational Medicine, University Hospital of Bari, Bari, Italy
Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 5, Pages 634–638, ISSN (Online) 14346621, ISSN (Print) 14374331, DOI: https://doi.org/10.1515/CCLM.2007.112, May 2007
- Published Online:
Background: Studies have suggested that soluble mesothelin-related protein (SMRP) can be used as a serum marker of malignant mesothelioma.
Methods: We assessed the analytical performance of the Mesomark (Fujirebio Diagnostic) two-step ELISA on an automated analyser and performed a preliminary clinical evaluation. The precision of the assay and the in vitro effect of interfering substances on SMRP concentrations were investigated. The serum marker was analysed in 109 healthy subjects never exposed to asbestos, 26 healthy subjects exposed to asbestos, 33 patients with asbestosis, 33 with asbestos-related pleural plaques, 10 with non-malignant pleural diseases, 30 with lung cancer and 24 with histological diagnosis of pleural mesothelioma.
Results: Using the International Mesothelioma Interest Group classification, there were nine stage IV, two stage III, four stage II and nine stage I patients. SMRP concentrations of 4.75, 11.0 and 14 nmol/mL showed a total imprecision of 3.5%, 3.1% and 3.8%. The detection limit was 0.035 nmol/mL; the mean SMRP concentration of 0.63 nmol/mL was associated with a coefficient of variation of 10%. There was no effect (p>0.05) of interfering substances. Serum samples from patients with established pleural mesothelioma had significantly higher (p<0.05) concentrations of SMRP than control healthy and patient groups.
Conclusions: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.
Clin Chem Lab Med 2007;45:634–8.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.